TOPLINEMassachusetts-based biotech company Moderna said Wednesday that in a small trial, its experimental coronavirus vaccine produced a similar number of antibodies for people aged 56 years and older as younger adults in a preliminary study, a promising sign for the high-risk age group amid concern that vaccines wouldn’t offer as much protection for older adults. Moderna tested its vaccine on 10 adults between the ages of 56 and 70 and 10 adults aged 71 and older and found that the older volunteers developed antibodies in a similar range as the younger volunteers; Moderna said the vaccine was well-tolerated with no serious side effects reported. The U.S. had already given $955 million to help Moderna research develop its vaccine through the Biomedical Advanced Research and Development Authority. He became a billionaire in April as Moderna stock jumped after announcing it expected to begin Phase 2 human trials for its Covid-19 vaccine. To Buy 100 Million Doses Of Moderna Coronavirus Vaccine (Forbes)Moderna CEO Stéphane Bancel Becomes A Billionaire As Stock Jumps On Coronavirus Vaccine News (Forbes)Fueled By $500 Million In Federal Cash, Moderna Races To Make A Billion Doses Of An Unproven Cure (Forbes)Full coverage and live updates on the Coronavirus

Source: Forbes August 26, 2020 16:18 UTC